Inotiv Broadens Pathology Service Offerings
January 19 2021 - 8:33AM
Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the
“Company”, “We”, “Our” or “Inotiv”), doing business as
Inotiv, a leading provider of nonclinical and analytical contract
research services, today announced the most recent hiring related
to the continued expansion of the Company’s pathology service
offerings through ongoing investment and key hires. Effective
January 18, 2021, Adam Aulbach, DVM, DACVP, joined the Company as
Director, Clinical Pathology.
“We assess the needs of our clients on an
ongoing basis and respond by enhancing our offerings,” said Dr.
Stewart Jacobson, Senior Vice President, Pathology. “The ability to
provide expertise in veterinary clinical pathology, and to
integrate that expertise with our already strong anatomic pathology
service, should create even greater value for our clients. Dr.
Aulbach’s extensive experience in clinical pathology and his unique
expertise in the area of experimental biomarkers adds to our
already-comprehensive suite of services. We’re excited to welcome
him to the Inotiv team.”
The Company’s pathology laboratories offer a full range of
services—pharmacology models to safety assessment, discovery
through approval—from standalone, single projects, through
fully-integrated, multidisciplinary programs. Inotiv’s
board-certified pathologists provide expert guidance in toxicologic
and investigative pathology, and support assay development for a
broad spectrum of studies, tissues, species, and disease
states.
Robert Leasure, Jr., the Company’s President and Chief Executive
Officer, commented, “Investing in the development of our pathology
services reflects our ongoing commitment to our strategy of growth
through addition of services, capacity, systems and talent to
deliver the broad scope and right-size solutions our clients
deserve.”
About the Company
The Company is a pharmaceutical development
company providing contract research services and monitoring
instruments to emerging pharmaceutical companies and the world's
leading drug development companies and medical research
organizations. The Company focuses on developing innovative
services supporting its clients’ discovery and development
objectives for improved decision-making and accelerated goal
attainment. The Company’s products focus on increasing efficiency,
improving data, and reducing the cost of taking new drugs to
market. Visit inotivco.com for more information about the
Company.
This release may contain forward-looking
statements that are subject to risks and uncertainties including,
but not limited to, risks and uncertainties related to changes in
the market and demand for our products and services, the
development, marketing and sales of products and services, changes
in technology, industry and regulatory standards, the timing of
acquisitions and the successful closing, integration and business
and financial impact thereof, the impact of the COVID-19 pandemic
on the economy, demand for our services and products and our
operations, including the measures taken by governmental
authorities to address the pandemic, which may precipitate or
exacerbate other risks and/or uncertainties and various other
market and operating risks, including those detailed in the
Company's filings with the U.S. Securities and Exchange
Commission.
FOR MORE INFORMATION: |
Company Contact: |
|
Beth A. Taylor |
|
Chief Financial Officer |
|
Phone: 765.497.8381 |
|
btaylor@inotivco.com |
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024